Azithromycin ophthalmic solution, 1% + Vehicle
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharitis
Conditions
Blepharitis
Trial Timeline
Dec 1, 2010 → Jun 1, 2011
NCT ID
NCT01269658About Azithromycin ophthalmic solution, 1% + Vehicle
Azithromycin ophthalmic solution, 1% + Vehicle is a phase 2 stage product being developed by Merck for Blepharitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01269658. Target conditions include Blepharitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01269658 | Phase 2 | Terminated |
Competing Products
15 competing products in Blepharitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lotilaner ophthalmic solution, 0.25% + Vehicle control | Tarsus Pharmaceuticals | Approved | 80 |
| TP-03 + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 3 | 72 |
| TP-03, 0.25% + TP-03 Vehicle | Tarsus Pharmaceuticals | Phase 2/3 | 60 |
| Lotilaner + Vehicle Control | LianBio | Phase 3 | 69 |
| ISV-305 | Sun Pharmaceutical | Phase 3 | 77 |
| ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone | Sun Pharmaceutical | Phase 3 | 77 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| AzaSite® | Merck | Approved | 85 |
| Azithromycin ophthalmic solution, 1% + Placebo | Merck | Phase 2 | 52 |
| Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment | Viatris | Phase 3 | 74 |
| GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID | Glaukos | Phase 2 | 49 |
| KPI-121 + Vehicle | Kala Pharmaceuticals | Phase 2 | 44 |